News | Cath Lab | January 08, 2016

Seeking Treatment Earlier May Improve Heart Attack Outcomes

Restoring blood flow quickly after heart attack symptoms begin key to less heart damage

heart attack outcomes, door-to-ballon time, symptoms, JACC Cardiovascular Interventions, PCI

January 8, 2016 — A new study published online in JACC: Cardiovascular Interventions reveals that delays in recognizing symptoms of heart attack patients and seeking treatment are associated with increased damage to the heart.

Door-to-balloon time is the time from when a heart attack patient arrives in the emergency room until percutaneous coronary intervention (PCI) is performed to restore blood flow. American College of Cardiology/American Heart Association (ACC/AHA) guidelines state that hospitals treating ST-segment elevation myocardial infarction (STEMI) patients with emergency PCI should do so within 90 minutes or less of reaching the hospital. The ACC launched the Door-to-Balloon (D2B) Alliance in 2006 to reduce the time to which STEMI patients receive PCI in U.S. hospitals.

According to the study, in about 90 percent of PCI cases blood flow is restored in the surface of the heart, but in about one-third of patients, blood flow is not restored to the heart muscle. Researchers in this study compared the impact of the time from heart attack symptom onset-to-balloon and door-to-balloon on heart muscle function.

Researchers reviewed the records of 2,056 patients in the multi-center Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial comparing patients with symptom onset-to-balloon time in three categories: two hours and less; more than two hours to four hours; and more than four hours.

Patients who took a total of two to four hours or longer to get treated with a balloon angioplasty were less likely to have blood flow fully restored and were more likely to die within three years than patients treated more quickly.

“The decrease in median door-to-balloon time in recent years has not resulted in a reduction in mortality in STEMI patients,” said Roxana Mehran, M.D., a study author and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine. “This study highlights the need to reconsider the role of door-to-balloon as a performance metric and examine the utility of a broader metric of systems delay such as first medical contact to balloon time as well as total ischemic time.”

In an accompanying editorial, Michael A. Kutcher, M.D., of Wake Forest Baptist Medical Center, said the door-to-balloon metric and systems in place are extremely valuable and should continue; however, physicians need to pay attention to associated metrics such as the symptoms and signs of the onset of ischemia, which is loss of blood flow. He attributed the lack of significant improvement in mortality and morbidity with reduced door-to-balloon time to the fact that microvascular damage can still occur with shorter door to balloon times and can lead to increased risk of death.

“Patients with prolonged symptom onset-to-balloon time are a high-risk group and should be treated accordingly with assertive strategies,” Kutcher said. “We as an interventional cardiology community should continue to educate the public and health care providers regarding the importance to quantify symptom onset-to-balloon time and follow through with prompt action.”

For more information: www.interventions.onlinejacc.org

Related Content

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav